MediWound to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

YAVNE, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum taking place on November 19th at the Westin Grand Central Hotel in New York City. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's presentation on Thursday, November 19th at 3:30 p.m. Eastern time.

Mr. Cohen's presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company's website at A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.

About MediWound Ltd.

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli and Argentinean Ministries of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit

CONTACT: Sharon Malka Chief Financial & Operations Officer MediWound Anne Marie Fields Senior Vice President LHA 212-838-3777